News

Over the years, IKA has become an invaluable resource for eye care professionals.

The company noted that the product is a sterile, single-patient use, physician administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.

The vision care company is joining forces with the global nonprofit to fight avoidable blindness around the world.

According to the company, ONL1204 is a first-in-class small molecule Fas inhibitor with a mechanism of action designed to provide neuroprotection for retinal cells.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

The Bascom Palmer program showcases neovascular, exudative, and degenerative eye diseases, and is designed for retina specialists, general ophthalmologists and researchers.

In a news release, the CDC is urging that clinicians and patients immediately discontinue the use of EzriCare Artificial Tears until the epidemiological investigation and laboratory analyses are complete.

A leader in the field of ophthalmology, Cynthia Matossian, MD, FACS, ABES, discusses her career as she prepares for the next phase.

Effective networking involves developing relationships with other people, sharing relevant information and resources, and providing mutual support and encouragement on the path to reaching your goals.

According to the company, the approval allows Eyenuk’s EyeArt AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss.

With donations, the West Virginia University Department of Ophthalmology and Visual Sciences has added two new pieces of ophthalmic training equipment to its lab.

Specialists seek more information for use in the treatment of patients diagnosed with retinal diseases

Physicians explain how winter exacerbates symptoms of disease.

HG004 aims to be more effective than other AAV2 products in treatment of inherited retinal diseases caused by mutations in the RPE65 gene.

The workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.

Minimally invasive, novel system achieves significant pressure level reductions.

Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.

Tailored approach can help physicians provide better outcomes for patients

The technique could provide researchers with samples for studying AMD and other eye diseases.

In preclinical models, investigators at Brigham and Women’s Hospital uncovered a novel mechanism underlying the development of diabetic cataracts that undermines current hypothesis

Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, speak with Ophthalmology Times® on what attendees can expect from the upcoming meeting, being held Feb. 2-4 in downtown San Francisco.

On this week's episode of the NeuroOp Guru video blog, Andy Lee, MD, and Elizabeth Fortin, MD, discuss the comparison of the range of lumbar CSF pressure in adults with normal CSF pressure and in idiopathic intracranial hypertension.

Vial will be supporting RecensMedical with the phase 3 clinical trial for its Ocu-Cool system.

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 10, 2023.

Several strategies exist to improve safety of injections for patients.

According to the company, it is planning to hold an end-of-phase 2 meeting with the FDA to discuss the results.

The Phase 2 clinical trial will evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.

Based on their findings, an international team of researchers is discouraging the application of atropine as a standard therapy for trabeculectomy surgery.

The intent of the award is to recognize early-career researchers who have exhibited excellence in research, as well as their fundamental scientific discoveries, concepts and novel technologies which have led to, or have the promise of leading to, clinical application.